Tyrosine 547 Constitutes an Essential Part of the Catalytic Mechanism of Dipeptidyl Peptidase IV*

Human dipeptidyl peptidase IV (DPP-IV) is a ubiquitously expressed type II transmembrane serine protease. It cleaves the penultimate positioned prolyl bonds at the N terminus of physiologically important peptides such as the incretin hormones glucagon-like peptide 1 and glucose-dependent insulinotropic peptide. In this study, we have characterized different active site mutants. The Y547F mutant as well as the catalytic triad mutants S630A, D708A, and H740L showed less than 1% wild type activity. X-ray crystal structure analysis of the Y547F mutant revealed no overall changes compared with wild type apoDPP-IV, except the ablation of the hydroxyl group of Tyr547 and a water molecule positioned in close proximity to Tyr547. To elucidate further the reaction mechanism, we determined the crystal structure of DPP-IV in complex with diisopropyl fluorophosphate, mimicking the tetrahedral intermediate. The kinetic and structural findings of the tyrosine residue are discussed in relation to the catalytic mechanism of DPP-IV and to the inhibitory mechanism of the 2-cyanopyrrolidine class of potent DPP-IV inhibitors, proposing an explanation for the specificity of this class of inhibitors for the S9b family among serine proteases.

[1]  G. Sutherland,et al.  Cloning, expression and chromosomal localization of a novel human dipeptidyl peptidase (DPP) IV homolog, DPP8. , 2000, European journal of biochemistry.

[2]  C. Morimoto,et al.  Serum high molecular weight dipeptidyl peptidase IV (CD26) is similar to a novel antigen DPPT-L released from activated T cells. , 1996, Journal of immunology.

[3]  Robert Huber,et al.  The crystal structure of dipeptidyl peptidase IV (CD26) reveals its functional regulation and enzymatic mechanism , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[4]  L. Polgár,et al.  Transition-state stabilization at the oxyanion binding sites of serine and thiol proteinases: hydrolyses of thiono and oxygen esters. , 1983, Biochemistry.

[5]  G. Vanhoof,et al.  Use of immobilized adenosine deaminase (EC 3.5.4.4) for the rapid purification of native human CD26/dipeptidyl peptidase IV (EC 3.4.14.5). , 1996, Journal of immunological methods.

[6]  Bo Ahrén,et al.  Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes. , 2002, Diabetes care.

[7]  R J Read,et al.  Crystallography & NMR system: A new software suite for macromolecular structure determination. , 1998, Acta crystallographica. Section D, Biological crystallography.

[8]  Z. Otwinowski,et al.  [20] Processing of X-ray diffraction data collected in oscillation mode. , 1997, Methods in enzymology.

[9]  Alexei Finkelstein,et al.  Threading with chemostructural restrictions method for predicting fold and functionally significant residues: Application to dipeptidylpeptidase IV (DPP‐IV) , 2002, Proteins.

[10]  C. Abbott,et al.  The Family of CD26/DPIV and Related Ectopeptidases , 2002 .

[11]  A. Warshel,et al.  How do serine proteases really work? , 1989, Biochemistry.

[12]  V. Fülöp,et al.  Catalysis of serine oligopeptidases is controlled by a gating filter mechanism , 2000, EMBO reports.

[13]  L. Polgár Unusual secondary specificity of prolyl oligopeptidase and the different reactivities of its two forms toward charged substrates. , 1992, Biochemistry.

[14]  J. Holst,et al.  Inhibition of the activity of dipeptidyl-peptidase IV as a treatment for type 2 diabetes. , 1998, Diabetes.

[15]  C. Abbott,et al.  Two highly conserved glutamic acid residues in the predicted β propeller domain of dipeptidyl peptidase IV are required for its enzyme activity , 1999, FEBS letters.

[16]  P. Carter,et al.  Probing the mechanism and improving the rate of substrate-assisted catalysis in subtilisin BPN'. , 1991, Biochemistry.

[17]  Bo Ahrén,et al.  0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(5):2078–2084 Printed in U.S.A. Copyright © 2004 by The Endocrine Society doi: 10.1210/jc.2003-031907 Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels , 2022 .

[18]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[19]  D. Marguet,et al.  Structure of the mouse dipeptidyl peptidase IV (CD26) gene. , 1994, Biochemistry.

[20]  Sven Branner,et al.  Crystal structure of human dipeptidyl peptidase IV/CD26 in complex with a substrate analog , 2003, Nature Structural Biology.

[21]  G. Sutherland,et al.  Genomic organization, exact localization, and tissue expression of the human CD26 (dipeptidyl peptidase IV) gene , 1994, Immunogenetics.

[22]  D. Marguet,et al.  cDNA cloning for mouse thymocyte-activating molecule. A multifunctional ecto-dipeptidyl peptidase IV (CD26) included in a subgroup of serine proteases. , 1992, The Journal of biological chemistry.

[23]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[24]  J. Leunissen,et al.  Subtilases: The superfamily of subtilisin‐like serine proteases , 1997, Protein science : a publication of the Protein Society.

[25]  László Polgár,et al.  Prolyl Oligopeptidase An Unusual β-Propeller Domain Regulates Proteolysis , 1998, Cell.

[26]  J. V. Van Beeumen,et al.  A prediction of DPP IV/CD26 domain structure from a physico-chemical investigation of dipeptidyl peptidase IV (CD26) from human seminal plasma. , 1997, Biochimica et biophysica acta.

[27]  L. Polgár,et al.  Substrate‐ and pH‐dependent contribution of oxyanion binding site to the catalysis of prolyl oligopeptidase, a paradigm of the serine oligopeptidase family , 2008, Protein science : a publication of the Protein Society.

[28]  G. Glenner,et al.  A new dipeptide naphthylamidase hydrolyzing glycyl-prolyl-β-naphthylamide , 2004, Histochemie.

[29]  Koji Inaka,et al.  The structure and function of human dipeptidyl peptidase IV, possessing a unique eight-bladed β-propeller fold , 2003 .

[30]  Walter Huber,et al.  Structural basis of proline-specific exopeptidase activity as observed in human dipeptidyl peptidase-IV. , 2003, Structure.

[31]  G J Kleywegt,et al.  Recognition of spatial motifs in protein structures. , 1999, Journal of molecular biology.

[32]  Development of a tertiary-structure model of the C-terminal domain of DPP IV. , 2000, Advances in experimental medicine and biology.

[33]  T. Hughes,et al.  NVP-DPP728 (1-[[[2-[(5-cyanopyridin-2-yl)amino]ethyl]amino]acetyl]-2-cyano-(S)- pyrrolidine), a slow-binding inhibitor of dipeptidyl peptidase IV. , 1999, Biochemistry.

[34]  A. D'arcy,et al.  High-resolution structure of human apo dipeptidyl peptidase IV/CD26 and its complex with 1-[([2-[(5-iodopyridin-2-yl)amino]-ethyl]amino)-acetyl]-2-cyano-(S)-pyrrolidine. , 2003, Acta crystallographica. Section D, Biological crystallography.